VST BIO is a biotechnology company that develops antibodies for the treatment of inflammatory and cardiovascular diseases, including stroke and acute myocardial infarction, as well as sepsis.
Leading Cause of death worldwide
Of all patients are NOT eligible for standard therapy
Our VST Bio humanized antibody, delivered via a simple IV bolus infusion, reverses vascular disfunction and reduces inflammation in the brain.
The therapy can be given in the acute phase of the disease up to several days after onset of the ischemic stroke. Improved tissue perfusion and reduction of cerebral damage will lead to expedited recovery and reduction of persisting neurological symptoms.
Stroke is caused by the interruption of blood supply to the brain, due to a thrombus in one of the main cerebral arteries or hemorrhage. It estimated that 50% of the stroke damage is due to the loss of blood supply and 50% due to subsequent edema development.
Scientific Publications and Presentations
View our latest presentation:
Anti-Inflammatory Mechanisms of Anti-Sdc2 Mab VB-001 Contributing to
Neuroprotection After Ischemic Stroke
VST-Bio has a first-class managerial and advisory team consisting of experienced professionals in healthcare and business.